Are neuroticism and extraversion associated with the antidepressant effects of repetitive transcranial magnetic stimulation (rTMS)? An exploratory 4-week trial.

Depressive Disorders Program, Douglas Mental Health University Institute and McGill University, Montréal, Québec, Canada
Neuroscience Letters (Impact Factor: 2.06). 01/2013; DOI: 10.1016/j.neulet.2012.12.029
Source: PubMed

ABSTRACT Several randomized, controlled trials have found high frequency repetitive transcranial magnetic stimulation (HF-rTMS) to be effective for treating major depressive disorder (MDD), but its antidepressant mechanisms have yet to be firmly understood. In this context, pre-treatment personality traits and subsequent changes in personality concomitant to treatment may be relevant for our understanding of these mechanisms. To investigate this issue we conducted a naturalistic trial in which 14 subjects with moderate to severe depression were treated with daily HF-rTMS over the left dorsolateral prefrontal cortex for 4 weeks. Objective depressive symptoms (as assessed by the HAM-D(21)) and the major personality dimensions of neuroticism and extraversion were measured pre-post HF-rTMS. Pre-rTMS levels of extraversion predicted subsequent decrease in depressive symptoms. Also, HF-rTMS treatment resulted in a decrease in neuroticism scores, and this relative decrease was associated with the relative decrease in depression. Our results suggest that HF-rTMS may positively affect the personality dimension of neuroticism. Also, pre-treatment levels of extraversion may predict the subsequent antidepressant response to HF-rTMS. However, further studies with larger samples and controlled designs are needed to better clarify these preliminary findings.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although well-defined predictors of response are still unclear, clinicians refer a variety of depressed patients for a repetitive Transcranial Magnetic Stimulation (rTMS) treatment. It has been suggested that personality features such as Harm Avoidance (HA) and self-directedness (SD) might provide some guidance for a classical antidepressant treatment outcome. However, to date no such research has been performed in rTMS treatment paradigms. In this open study, we wanted to examine whether these temperament and character scores in particular would predict clinical outcome in refractory unipolar depressed patients when a typical high-frequency (HF)-rTMS treatment protocol is applied. Thirty six unipolar right-handed antidepressant-free treatment resistant depressed (TRD) patients, all of the melancholic subtype, received 10 HF-rTMS sessions applied to the left dorsolateral prefrontal cortex (DLPFC). All patients were classified as at least stage III TRD and were assessed with the Temperament and Character Inventory (TCI) before a HF-rTMS treatment. Only the individual scores on SD predicted clinical outcome. No other personality scales were found to be a predictor of this kind of application. Our results suggest that refractory MDD patients who score higher on the character scale SD may be more responsive to the HF-rTMS treatment.
    Psychiatry Research 08/2014; 220(1-2). DOI:10.1016/j.psychres.2014.07.084 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prognostication is poor in repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder (MDD). Personality traits, particularly extraversion and neuroticism, have attracted increasing attention for both trait- and state-dependent characteristics in predicting response to pharmacotherapy, psychotherapy, and more recently to therapeutic neuromodulation for MDD. The advent of deep rTMS (DTMS) allows stimulation of deeper cortical regions, and we aimed to prospectively characterize personality dimensions and antidepressant response to DTMS in treatment-resistant MDD. A convenience sample of 15 patients with treatment-resistant MDD received four weeks of daily sessions of DTMS (20Hz, 3,000 pulses/session) of the left dorsolateral prefrontal cortex (DLFPC). At baseline and at the conclusion of treatment, patients completed the Big Five Inventory, a five-factor assessment of major personality dimensions. Clinical response was measured using the 21-item Hamilton Depression Rating Scale. Four weeks of DTMS treatment was not associated with changes in personality measures. Clinical remission was associated with higher baseline levels of agreeableness (score ≥ 29: 100% sensitive and 72.7% specific) and conscientiousness (score ≥ 30: 75% sensitive and 81.8% specific). Levels of agreeableness and extraversion were linearly associated with antidepressant response. Neuroticism was not associated with the antidepressant effects of DTMS in this cohort. Five-factor personality assessment may have prognostic value in DTMS for resistant MDD. Agreeableness, extraversion, and conscientiousness are associated with decreases in depressive symptoms during treatment with DTMS.
    Neuroscience Letters 01/2014; 563. DOI:10.1016/j.neulet.2014.01.037 · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: -This chart review examined clinical, treatment parameter, and outcome data from 185 outpatients with medication-resistant major depression who received either 10 Hz (30 min) or intermittent theta burst (6 min) rTMS of the bilateral dorsomedial prefrontal cortex, under MRI guidance, at 120% resting motor threshold, in a single Canadian clinic (the Toronto Western Hospital) from April, 2011 to February, 2014.-There were no seizures or other serious adverse events over 7912 total runs of stimulation in 185 unique patients (10 Hz: 4274 runs, 2137 sessions, 98 patients; iTBS: 3638 runs, 1819 sessions, 87 patients). There were no significant differences between 10 Hz and iTBS patients in the rates of discontinuation for lack of response, adverse symptoms, or unspecified reasons.-Dichotomous outcomes did not differ significantly between groups (Response/remission rates: BDI-II: 10 Hz, 40.6%/29.2%; iTBS, 43.0%/31.0%. HamD17: 10 Hz, 50.6%/38.5%; iTBS, 48.5%/27.9%). On continuous outcomes, there was no significant difference between groups in pre-treatment or post-treatment scores, or percent improvement on either BDI-II of HamD17. Mixed-effects modelling revealed no significant group-by-time interaction on either measure.-Outcomes were non-normally distributed in both groups, with a trimodal distribution into non-responders, partial responders, and strong responders apparent on kernel density estimates of the distribution of outcomes in both groups on BDI-II and HamD17 measures.-Non-parametric comparisons of the cumulative distribution functions for the 10 Hz and iTBS groups also revealed no significant differences in outcomes on either BDI-II or HamD17 measures.-In terms of pace of improvement, mixed-effects models found no significant group by time interaction over the course of treatment, on either the BDI-II or HamD17 measures.-The results suggest that iTBS may be as safe and well-tolerated as 10 Hz stimulations requiring 5 times as many pulses and 5 times as much time to administer, while achieving equivalent outcomes. The implications of this finding for rTMS treatment costs and clinic capacities could be substantial. A randomized controlled trial comparing conventional 10 Hz stimulation to briefer iTBS protocols, at the conventional target in the left DLPFC, may be warranted.
    Brain Stimulation 11/2014; 8(2). DOI:10.1016/j.brs.2014.11.002 · 5.43 Impact Factor


Available from
May 22, 2014